SCHEMBL4714899

SCHEMBL4714899

O=c1ccc2c(cc(S(=O)(=O)N3CCCC3)n2Cc2cccc(Cl)c2)n1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 2/20 0.49
TRPV4 Q9HBA0 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712460 0.78 PTGS2 (0.51) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL5119050 0.76 CCR2 (0.62) MAPTMAPK8MAPK9
SCHEMBL4717102 0.75 MAPK8 (0.46) ALDH1A1KDM4ESIGMAR1MEN1KMT2A
SCHEMBL4715213 0.74 CCR2 (0.51) ALDH1A1KDM4EKMT2AMAPTLMNA
SCHEMBL4716161 0.73 MAPT (0.42) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL4711188 0.73 BRD4 (0.53) ALDH1A1KDM4EMAPTLMNAMAPK8
SCHEMBL4717022 0.73 CCR2 (0.49) ALDH1A1KDM4EMAPTLMNAMAPK8
SCHEMBL4715185 0.72 BRD4 (0.48) ALDH1A1KDM4EMAPTLMNAMAPK8
SCHEMBL4716315 0.71 ALDH1A1 (0.47) ALDH1A1KDM4ESIGMAR1MAPTLMNA
SCHEMBL4712174 0.71 MAPT (0.51) ALDH1A1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 ALDH1A1 3407/4885KDM4E 2030/4885TRPV4 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.